De Padua Suspended Two Years By USADA For Failed Test
After only being in one fight in the UFC, Isabela de Padua has felt the wrath of the United States Anti-Doping Agency.
The flyweight failed a test for an anabolic steroid called Nandrolone, a form of testosterone. Following an in-competition test on November 16, in which she lost to Ariane Lipski via unanimous decision, de Padua (5-2) tested positive for 19-norandrosterone (19-NA). She also had a urine test conducted on December 19.
“In accordance with standard practice, the exogenous, or non-natural, origin of the 19-NA was further confirmed by sophisticated carbon isotope-ratio mass spectrometry (GC/C/IRMS) analysis, which can reveal the presence of anabolic agents,” USADA stated in a press release. “In this case, the GC/C/IRMS analysis result was consistent with the exogenous origin of 19-NA. 19-norsteroids, including nandrolone and its precursors, are non-Specified Substances in the class of Anabolic Agents and prohibited at all times under the UFC Anti-Doping Policy and UFC Prohibited List.”
de Padua did not disclose information regarding all medications and supplements she was taking over the past twelve months. As a result, the option for a reduction of the sentence was not possible. The official USADA site shares information on how to understand the rules.
USADA recognizes the starting point of the ineligibility period to be November 16, 2019, meaning de Padua can return to action in November 2021. She will also be monitored by the Brazilian commission during her sentence, in the case she wants to try and fight outside of the UFC.